Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

April 17-18, 2015

New York, New York

Continuing Education

Imedex®, LLC is accredited by the Continuing Education Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum of 14.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend

These educational activities are specifically designed for hematologists, medical oncologists, and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with hematologic malignancies.

Objectives

Upon successful completion of these educational activities, participants should be able to:

  • Evaluate recently finalized and ongoing clinical trial data for standard of care and novel therapies and assess how their integration into current therapeutic strategies has the potential to impact clinical outcomes
  • Define patient populations who will most likely receive optimal benefit from therapeutic or maintenance regimens
  • Interpret how genetic and molecular abnormalities can be utilized in disease diagnosis, prognosis, and monitoring
  • Assess clinical trial data pertaining to novel therapies and understand their mechanisms of action in the treatment of hematologic malignancies and benign hematologic disorders
  • Formulate evidence-based strategies for the management of hematologic malignancies and benign hematologic disorders through selection of optimal therapies (current and investigational) and consideration of patient physical and genetic risk factors